Form 4: Oramed CFO Gabay Acquires 19,000 Shares via PSU Vesting

Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay acquired 19,000 shares of common stock through the vesting of performance stock units.

Summary

• Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals Inc. (ORMP), acquired 19,000 shares of common stock.
• The acquisition occurred on January 22, 2026, through the vesting of performance stock units (PSUs).
• The PSUs were granted on December 31, 2025, and vested because the company's common stock achieved a specified price per share.
• The shares were received for no consideration upon vesting.
• Following this transaction, Mr. Gabay beneficially owns 649,256 shares of Oramed Pharmaceuticals Inc. common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it indicates that performance criteria for the PSUs were met, which typically aligns with positive company performance or stock appreciation. However, it is a routine compensation event and not a direct investment decision by the insider.

Positives

• The vesting of performance stock units indicates that Oramed Pharmaceuticals Inc.'s common stock achieved a specified price per share, suggesting positive stock performance or operational milestones were met.

Negatives

• The issuance of 19,000 new shares, while part of a compensation plan, represents a minor dilutive event for existing shareholders.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider filings like Form 4, especially those related to equity compensation vesting, are common across all industries. They reflect standard executive compensation practices tied to performance metrics, rather than specific industry trends.

Stakeholder Impact

• Shareholders: Experience minor dilution from the issuance of new shares, but the vesting indicates performance criteria were met, which could be seen positively.
• Employees (specifically Avraham Gabay): Benefits directly from the vesting of equity compensation, aligning executive incentives with company performance.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of performance stock units for a company executive. While it indicates that certain performance criteria were met, it does not provide sufficient new information to warrant a change in investment recommendation. It is a standard compensation event and not a discretionary purchase or sale that would signal a strong change in insider sentiment.

Keywords

Oramed Pharmaceuticals, ORMP, Avraham Gabay, CFO, Form 4, Insider Transaction, Performance Stock Units, PSU Vesting, Common Stock, Equity Compensation